



Domain Therapeutics to Participate in Upcoming Investor and Industry Conferences

Strasbourg, France – Montreal, Canada, February 6th, 2023 – Domain Therapeutics (“Domain” or “the Company”), a drug discovery and development company focused on G Protein-Coupled Receptors (GPCRs) in immuno-oncology (IO), today announces investor and industry conferences that its Chief Executive Officer, Pascal Neuville, will attend or speak at in the first half of 2023.

[OBIO Investor Summit](#), World Trade Centre, Toronto, Canada – **8-9 February**

- Presentation slot: 9th February, 3:30 p.m., Room C/D

[LSX World Congress](#), London, UK – **3-4 May**

[BioEquity](#), Dublin, Ireland – **14-16 May**

- Presentation slot: to be announced at a later date

- ENDS -

For more information, please contact:

Consilium Strategic Communications

Amber Fennell, Namrata Taak, Maya Bennison

Email: DomainTherapeutics@consilium-comms.com

Tel: +44 (0)20 3709 5813

NewCap (for French media)

Annie-Florence Loyer

Email: afloyer@newcap.fr

Tel: +33 (0)1.44.71.02.12

About Domain Therapeutics

Domain Therapeutics, a biopharmaceutical company operating in France and Canada, focuses on developing innovative immunotherapies targeting G Protein-Coupled Receptors (GPCRs), one of the most important drug target classes, to unlock new possibilities in cancer. As a leader in GPCRs in immuno-oncology, Domain sees cancer differently, using a precise biomarker strategy to address the specific needs of patients based on unique signatures of individual cancers. Backed by decades of research and validated by multiple pharma partnerships, the Company’s unrivalled discovery engine enables rigorous GPCR target identification and selection.

Domain's clinical-stage programs include the A2aR/A2b receptor antagonist, identified during a research collaboration with Merck KGaA, and DT-9081, its fully owned EP4 receptor antagonist. The Company is also progressing an anti-CCR8 asset alongside a rich, optimized pipeline of first-in-class GPCR targets selected through Domain's drug discovery platform.

The Company raised €39m (\$42m) in early 2022 to develop high-value drug candidates to address GPCR-mediated immunosuppression in immuno-oncology. Domain is backed by a syndicate of leading international venture capital funds from Europe, Asia and North America.

For more information, please visit:

www.domaintherapeutics.com